Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have earned an average rating of "Moderate Buy" from the eight research firms that are covering the stock, MarketBeat reports...